ADCendo is a startup company based on an antibody-drug-conjugate, which is capable of curing cancer in a mouse model of disease
Eximmium generates novel therapeutic antibodies for the comprehensive treatment of cancer.
FerroSens offers the world’s first non-invasive screening device for iron deficiency at the point-of-care.
ImmuCon develops a proprietary “first-in class” monoclonal antibody against IL-3 for treatment of patients with systemic lupus erythematosus (SLE).
Isanans Pharma is working for improved vision
ISD is developing a first-in-class peptide therapy for severe systemic lupus erythematosus (SLE) targeting STimulator of INterfereon Genes (STING)
Digital therapy for bipolar disorder and schizophrenia.
Giving PKU patients a shot at normal life
UGISense uses its platform technology to develop antisense drugs in collaboration with industrial partners.
aBACTER is an innovative project team focused on the development of novel antibiotics exhibiting excellent potency against WHO-priority pathogens.
Our vision is to reduce cancer mortality by predicting the most efficient cancer treatments for individual patients and to accelerate drug discovery.
Pioneering epigenetic immune cell diagnostics
Providing new injectable biomatrix to treat early stage disc degeneration as well as early osteoarthritis in the knee and hip.
We are democratizing the genetic testing via HuluFISH technology.
Silvacx is an emerging startup developing rationally designed, nanoparticle-based immunotherapeutics against cancer and infectious diseases.
Reimagining ADCs: Expanding Therapeutic Opportunities and Capturing Unexplored Value.